Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Alice Susannah Bexon"'
Autor:
T.R. Jeffry Evans, Nehal J. Lakhani, Hendrik-Tobias Arkenau, Meredith McKean, Stefan N. Symeonides, Fabio Massaiti Iwamoto, Jim Rotolo, Gina Capiaux, Rob Michel, Stephen Kaesshaefer, Alice Susannah Bexon, Gerald Steven Falchook
Publikováno v:
Journal of Clinical Oncology. 40:3014-3014
3014 Background: The oncogenic transcription factor CCAAT/enhancer-binding protein β (C/EBPβ) promotes tumor survival and proliferation and inhibits differentiation. ST101 is a peptide antagonist of C/EBPβ, with anti-tumor activity in prostate can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1eb563063a25cd43a024d324d95bc30
https://doi.org/10.1200/jco.2022.40.16_suppl.3014
https://doi.org/10.1200/jco.2022.40.16_suppl.3014
Autor:
Jose Lutzky, Thomas Urban Marron, Steven Francis Powell, Daniel H. Johnson, Manish Patel, Anthony B. El-Khoueiry, John Sarantopoulos, Saida Dadi-Mehmetaj, Luke Russell, Stephen J. Russell, Kah Whye Peng, Stephen Kaesshaefer, Giuseppe Gullo, Alice Susannah Bexon, Mario Sznol
Publikováno v:
Journal of Clinical Oncology. 40:TPS9595-TPS9595
TPS9595 Background: There is a need for novel immunotherapies to address the patient population that never or no longer responds to immune checkpoint inhibitors (CPI). VV1 is an oncolytic vesicular stomatitis virus engineered to express human interfe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ef3333fe649ad3a23555502f81dd518
https://doi.org/10.1200/jco.2022.40.16_suppl.tps9595
https://doi.org/10.1200/jco.2022.40.16_suppl.tps9595
Autor:
Shruthi Naik, Bradley C. Leibovich, Tanner Miest, Stephen Bardot, Paul R Young, Stephen A. Boorjian, Mark L. Gonzalgo, Loren Herrera Hernandez, Matthew K. Tollefson, Jeffrey Karnes, Paige Nichols, Tessa Kroeninger, Rachel Graham, Monica Reckner, Alysha Newsom, Nandakumar Packiriswamy, Kah Whye Peng, Erol Wiegert, Alice Susannah Bexon
Publikováno v:
Journal of Clinical Oncology. 40:509-509
509 Background: Bladder cancer is a leading cause of cancer death in the United States. The histology in > 90% of cases is urothelial carcinoma (UC). Tumors may present either as non-muscle-invasive (NMIBC) or muscle-invasive disease (MIBC). Current
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc9cdf9383f47f9bfbcdab70bf8c0425
https://doi.org/10.1200/jco.2022.40.6_suppl.509
https://doi.org/10.1200/jco.2022.40.6_suppl.509